Who is the CEO of Idorsia Ltd?

Mr. Andre C. Muller is a business executive who currently serves as the CEO of Idorsia Ltd.

What is the Revenue Growth of Idorsia Ltd?

The Average Revenue growth for Idorsia Ltd according to last quarter updates is -26.17%.

What is Idorsia Ltd operating Margin?

Idorsia Ltd operating margin is -329.83% which shows how much profit IDIA.SW earns from each dollar of sales, after subtracting the direct costs tied to generating that revenue.

In which market sector does Idorsia Ltd operate?

Idorsia Ltd falls under the Healthcare sector which thrives across multiple industries. It stays competitive through its diverse product lineup, which spans computer hardware, tech gadgets, video streaming services, and cloud computing solutions.

What is Idorsia Ltd revenue growth?

Idorsia Ltd has Revenue Growth of -26.17% according to the last quarter update.

Idorsia Ltd

IDIA.SW•SIX

HealthcareBiotechnology

$1.31

$0.03(2.18%)

Idorsia Ltd (IDIA.SW) Stock Overview

Explore Idorsia Ltd’s financial performance, market position, analyst ratings, and future outlook.

Revenue Growth

-26.17%

↓ 26.17%

Profit Growth

$-1.40

↑ 11.47%

EPS Growth

$-1.40

↑ 13.17%

Operating Margin

-329.83%

↑ 9.07%

ROE

24.43%

↑ 11.47%

Dividend Yield

0.00%

Analyst Recommendations data is not available for IDIA.SWAnalyst Recommendations details for IDIA.SW are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Idorsia Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Idorsia Ltd has a collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; license agreement with Mochida Pharmaceutical for the supply, co-development, and comarketing of daridorexant; and Hoffman-La Roche Inc. to develop and market compounds in the field of cancer immunotherapy. It also has a collaboration with Antares Pharma, Inc. for the development of a self- administered drug device product for Selatogrel; and Neurocrine Biosciences, Inc. to develop and commercialize ACT-709478, which is in Phase II clinical trial for the treatment of epilepsy. The company was incorporated in 2017 and is headquartered in Allschwil, Switzerland.

CEO

Mr. Andre C. Muller

Employees

636

Headquarters

Hegenheimermattweg 91, Allschwil

Founded

2017